Profile data is unavailable for this security.
About the company
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)1.52bn
- Net income in CNY-1.55bn
- Incorporated2008
- Employees3.62k
- LocationRemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
- Phone+86 5 353573685
- Fax+86 5 356113517
- Websitehttp://www.remegen.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions Ltd | 825.18m | -377.67m | 9.83bn | 1.17k | -- | 11.61 | -- | 11.92 | -0.9121 | -0.9121 | 1.99 | 2.05 | 0.3533 | 1.00 | 6.83 | 707,092.40 | -16.17 | -23.62 | -26.76 | -30.81 | 69.81 | 79.76 | -45.77 | -106.72 | 0.716 | -27.47 | 0.4531 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 169.42m | -1.07bn | 9.99bn | 1.40k | -- | 5.21 | -- | 58.97 | -2.69 | -2.69 | 0.424 | 4.80 | 0.0379 | 0.089 | 9.74 | 113,628.50 | -24.10 | -37.61 | -30.74 | -45.95 | 90.50 | 81.54 | -636.41 | -2,112.26 | 1.25 | -41.98 | 0.5339 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Joinn Laboratories China Co Ltd | 2.12bn | -912.86k | 13.26bn | 2.59k | -- | 1.81 | -- | 6.24 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| InnoCare Pharma Ltd | 898.92m | -375.51m | 13.35bn | 1.09k | -- | 3.46 | -- | 14.85 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| RemeGen Co Ltd | 1.52bn | -1.55bn | 15.44bn | 3.62k | -- | 7.98 | -- | 10.14 | -2.88 | -2.88 | 2.83 | 4.35 | 0.2712 | 0.4446 | 5.00 | 421,122.40 | -27.65 | -18.66 | -36.21 | -23.69 | 78.65 | 81.64 | -101.95 | -102.21 | 0.9558 | -32.19 | 0.5167 | -- | 40.26 | 141.16 | -51.30 | -- | 59.07 | -- |
| Sinocelltech Group Ltd | 2.45bn | -24.64m | 19.14bn | 2.33k | -- | -- | -- | 7.83 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 389.64m | -837.22m | 19.19bn | 581.00 | -- | 44.80 | -- | 49.26 | -2.04 | -2.04 | 0.9471 | 1.03 | 0.235 | 0.4033 | 6.15 | 670,632.10 | -56.00 | -46.02 | -83.89 | -52.99 | 97.17 | 57.53 | -238.28 | -2,081.54 | 1.66 | -193.39 | 0.674 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
Data as of Nov 14 2024. Currency figures normalised to RemeGen Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
38.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 12.12m | 7.57% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 7.59m | 4.74% |
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 6.65m | 4.15% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 6.60m | 4.12% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 6.23m | 3.89% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 5.74m | 3.58% |
| Huatai Securities (Shanghai) Asset Management Co., Ltd.as of 31 Mar 2023 | 5.44m | 3.40% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 3.73m | 2.33% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 3.72m | 2.32% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 3.12m | 1.95% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
